Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher
November 11 2024 - 1:46PM
AllPennyStocks.com
This late-stage clinical trial company focuses on preventing
inflammation and acute organ injury. It is developing a platform of
new drugs to prevent inflammation in the kidneys, liver and
lungs...
To read the full story on AllPennyStocks.com, click
here.
ARch Biopartners (QB) (USOTC:ACHFF)
Historical Stock Chart
From Dec 2024 to Jan 2025
ARch Biopartners (QB) (USOTC:ACHFF)
Historical Stock Chart
From Jan 2024 to Jan 2025
